HRP20100276T1 - Gaboksadol za liječenje depresije i drugih afektivnih poremećaja - Google Patents

Gaboksadol za liječenje depresije i drugih afektivnih poremećaja Download PDF

Info

Publication number
HRP20100276T1
HRP20100276T1 HR20100276T HRP20100276T HRP20100276T1 HR P20100276 T1 HRP20100276 T1 HR P20100276T1 HR 20100276 T HR20100276 T HR 20100276T HR P20100276 T HRP20100276 T HR P20100276T HR P20100276 T1 HRP20100276 T1 HR P20100276T1
Authority
HR
Croatia
Prior art keywords
gaboxadol
treating depression
pharmaceutical composition
oral dose
affective disorders
Prior art date
Application number
HR20100276T
Other languages
English (en)
Inventor
Sanchez Connie
Ebert Bjarke
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20100276T1 publication Critical patent/HRP20100276T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Primjena gaboksadola kao monoterapije, naznačena time što se koristi za pripremu farmaceutske kompozicije za liječenje depresije, pri čemu farmaceutska kompozicija sadrži od 2.5 mg do 20 mg, kao što je 5 mg do 15 mg gaboksadola. Patent sadrži još 6 patentnih zahtjeva.

Claims (7)

1. Primjena gaboksadola kao monoterapije, naznačena time što se koristi za pripremu farmaceutske kompozicije za liječenje depresije, pri čemu farmaceutska kompozicija sadrži od 2.5 mg do 20 mg, kao što je 5 mg do 15 mg gaboksadola.
2. Primjena prema patentnom zahtjevu 1, naznačena time što je gaboksadol u obliku kisele adicijske soli, hidrata amfoternog iona ili anhidrata amfoternog iona.
3. Primjena prema bilo kojem od patentnih zahtjeva 1-2, naznačena time što je gaboksadol u obliku farmaceutski prihvatljive kisele adicijske soli izabrane od klorovodične ili bromovodične soli, ili u obliku monohidrata amfoternog iona.
4. Primjena prema bilo kojem od patentnih zahtjeva 1-3, naznačena time što je gaboksadol u obliku oralne doze.
5. Primjena prema bilo kojem od patentnih zahtjeva 1-4, naznačena time što je gaboksadol u obliku čvrste oralne doze, kao što su tablete ili kapsule, ili u obliku tekuće oralne doze.
6. Primjena prema bilo kojem od patentnih zahtjeva 1-5, naznačena time što je navedeni gaboksadol kristalan.
7. Primjena prema bilo kojem od patentnih zahtjeva 1-6, naznačena time što je navedena kompozicija namijenjena za liječenje čovjeka koji ima depresiju.
HR20100276T 2003-06-25 2010-05-18 Gaboksadol za liječenje depresije i drugih afektivnih poremećaja HRP20100276T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48301903P 2003-06-25 2003-06-25
DKPA200300956 2003-06-25
US53512304P 2004-01-07 2004-01-07
DKPA200400016 2004-01-07
PCT/DK2004/000459 WO2004112786A2 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Publications (1)

Publication Number Publication Date
HRP20100276T1 true HRP20100276T1 (hr) 2010-06-30

Family

ID=33545397

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100276T HRP20100276T1 (hr) 2003-06-25 2010-05-18 Gaboksadol za liječenje depresije i drugih afektivnih poremećaja

Country Status (17)

Country Link
EP (2) EP2145620A3 (hr)
JP (1) JP2007508236A (hr)
AT (1) ATE459353T1 (hr)
AU (1) AU2004248890A1 (hr)
BR (1) BRPI0410857A (hr)
CY (1) CY1110046T1 (hr)
DE (1) DE602004025808D1 (hr)
DK (1) DK1641456T3 (hr)
ES (1) ES2341004T3 (hr)
HR (1) HRP20100276T1 (hr)
IL (2) IL172631A0 (hr)
MX (1) MXPA05013016A (hr)
NZ (1) NZ543586A (hr)
PL (1) PL1641456T3 (hr)
PT (1) PT1641456E (hr)
SI (1) SI1641456T1 (hr)
WO (1) WO2004112786A2 (hr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663218A1 (en) * 2003-09-10 2006-06-07 MERCK SHARP &amp; DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
CA2548917C (en) 2003-12-11 2014-09-23 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US20050267176A1 (en) 2004-02-18 2005-12-01 Sepracor Inc. Dopamine-agonist combination therapy for improving sleep quality
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
WO2006083682A2 (en) * 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
WO2006118897A1 (en) * 2005-04-29 2006-11-09 H.Lundbeck A/S Acid and base salt forms of gaboxadol
TW200920358A (en) * 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
DK3274331T3 (da) 2015-03-24 2020-03-23 H Lundbeck As Fremstilling af 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CN112601524A (zh) * 2018-04-06 2021-04-02 奥维德医疗公司 加波沙朵在治疗物质使用障碍中的用途
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
AU2019384561A1 (en) * 2018-11-21 2021-06-10 Certego Therapeutics Inc. Combination of gaboxadol and lithium for the treatment of psychiatric disorders
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
KR20210105387A (ko) 2018-12-17 2021-08-26 오비드 테라퓨틱스 인크. 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용
CN114786669A (zh) 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc A canceled gaboxadol ring and its use for the treatment of psychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
HUP0400051A2 (hu) 2001-05-21 2004-04-28 H. Lundbeck A/S Gabodaxolt tartalmazó granulált készítmények és eljárás az előállításukra

Also Published As

Publication number Publication date
WO2004112786A2 (en) 2004-12-29
NZ543586A (en) 2009-07-31
CY1110046T1 (el) 2015-01-14
EP2145620A3 (en) 2010-03-17
IL202106A0 (en) 2010-06-16
AU2004248890A1 (en) 2004-12-29
JP2007508236A (ja) 2007-04-05
PL1641456T3 (pl) 2010-08-31
DK1641456T3 (da) 2010-06-21
SI1641456T1 (sl) 2010-06-30
MXPA05013016A (es) 2006-03-02
DE602004025808D1 (de) 2010-04-15
ES2341004T3 (es) 2010-06-14
ATE459353T1 (de) 2010-03-15
IL172631A0 (en) 2006-04-10
EP1641456A2 (en) 2006-04-05
WO2004112786A3 (en) 2005-04-14
BRPI0410857A (pt) 2006-07-04
EP2145620A2 (en) 2010-01-20
PT1641456E (pt) 2010-06-01
EP1641456B1 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
HRP20100276T1 (hr) Gaboksadol za liječenje depresije i drugih afektivnih poremećaja
MX2009011755A (es) Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MA32692B1 (fr) Procede de liberation d&#39;une composition pharmaceutique a un patient qui en a besoin
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
HRP20221269T1 (hr) Pripravci za liječenje mijelofibroze
BR0215148A (pt) Composições farmacêuticas de agonista parcial 5ht4
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
RU2012142811A (ru) Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
MX2007012300A (es) Uso de nefopam y analogos del mismo para el tratamiento de un sindrome caracterizado por dolor cronico y fatiga.
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
TW200603816A (en) Risedronate compositions and their methods of use
BR0214497A (pt) Composição farmacêutica que compreende um agonista do receptor 5ht1
IL168704A (en) Calcilytic compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating disease or disorder characterized by abnormal bone or mineral homeostasis
MXPA05011476A (es) Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
WO2007062862A3 (en) Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
Hong et al. Role of central α2-adrenoceptors on the development of muricidal behavior in olfactory bulbectomized rats: Effect of α2-adrenoceptor antagonists
WO2005121074A3 (en) Processes for the preparation of sertraline hydrochloride
HRP20090102T3 (hr) Poboljšana farmaceutska smjesa koja sadrži ace inhibitor i postupak za njeno pripravljanje
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine